David S. Rosenbloom
Executive VP & General CounselMr. David S. Rosenbloom serves as General Counsel at Baxter International Inc. since April 2022 and joined Baxter in 2022 and served as its Senior Vice President since April 2022 until 2023 and serves as its Executive Vice President since 2023 . He served as Global Head of Litigation Practice Group of McDermott Will & Emery, LLP. He focuses his practice on the areas of defense of criminal investigations and trials, qui tam litigation, healthcare fraud and abuse compliance, internal investigations and complex commercial litigation. Mr. Rosenbloom has experience in defending healthcare providers and manufacturers as well as handling criminal antitrust defense and Securities and Exchange Commission (SEC) matters. Mr. Rosenbloom has represented numerous corporate and individual clients in connection with government investigations, including serving as lead defense counsel in jury trials that resulted in acquittals for individual and corporate defendants. He also has represented special committees of the Board of Directors of public corporations conducting internal investigations. Previously, he served in the US Attorney’s Office for the Northern District of Illinois, at the conclusion of which he held the position of deputy Chief of the General Crimes Division. As an assistant US attorney, he conducted and supervised investigations concerning allegations of financial misconduct and fraud, including government program and healthcare fraud. Mr. Rosenbloom also successfully tried federal jury trials involving a wide variety of matters, including financial crimes, securities fraud, public corruption and racketeering. Mr. Rosenbloom serves on the adjunct faculty at Northwestern University School of Law, where he teaches trial advocacy. He earned JD magna cum laude in 1985 from Harvard Law School and BA magna cum laude in 1982 from Colorado College.
公司職務
- 公司名稱Baxter International Inc.股票代碼BAX職務Executive VP & General Counsel共事同僚
- APAndrew P. HiderCEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director
- DBDavid Brent ShaferIndependent Chairman of the Board
- MSMaria SorianoGroup President of Infusion Therapies & Platforms
- JTJohn Terence RogersExecutive VP & CFO
- BHBernie HeineInterim Chief Accounting Officer & Controller
- PBPatricia B. MorrisonIndependent Director
- NMNancy M. SchlichtingIndependent Director
- WAWilliam A. AmpofoIndependent Director
